Non-Hormonal Drug Reduced Hot Flashes From Endocrine Therapy for Breast Cancer

(MedPage Today) — CHICAGO — The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women receiving endocrine therapy for hormone receptor (HR)-positive breast cancer or its prevention, the phase…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115878

Author :

Publish date : 2025-06-03 17:36:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

Non-Hormonal Drug Reduced Hot Flashes From Endocrine Therapy for Breast Cancer

Super-invasive termites could spread from Florida around the world

TAVR System Dropped; Treprostinil Powder Approved; Post-MI Cancer

Related Posts

Nefecon Shows IgAN Benefits Regardless of Baseline eGFR

Why Choose Second Opinions? Risky Cancer Searches; 18 Months to Live, 20 Years Later

Global Stroke Deaths Still a Concern, and It’s Not Just About Developing Countries

How Trump’s Pick for Surgeon General Uses Her Big Online Following to Make Money

Women find other women’s faces even more attractive than men do

GLP-1 Drug Can Cause Rare, Potentially Blinding Side Effect, EMA Warns

Nefecon Shows IgAN Benefits Regardless of Baseline eGFR

Why Choose Second Opinions? Risky Cancer Searches; 18 Months to Live, 20 Years Later

Global Stroke Deaths Still a Concern, and It’s Not Just About Developing Countries

How Trump’s Pick for Surgeon General Uses Her Big Online Following to Make Money

Women find other women’s faces even more attractive than men do

GLP-1 Drug Can Cause Rare, Potentially Blinding Side Effect, EMA Warns

Experts Suggest NHS Heart Risk Checks from Age 25

Experimental MS Drug Nearly Eliminates Disease Activity

Categories

Archives